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Abstract
Proteoglycans in bladder tumors are modified with a distinct oncofetal chondroitin sulfate (ofCS) glycosaminoglycan
that is normally restricted to placental trophoblast cells. This ofCS-modification can be detected in bladder tumors by
the malarial VAR2CSA protein, which in malaria pathogenesis mediates adherence of parasite-infected erythrocytes
within the placenta. In bladder cancer, proteoglycans are constantly shed into the urine, and therefore have the
potential to be used for detection of disease. In this study we investigated whether recombinant VAR2CSA (rVAR2)
protein could be used to detect ofCS-modified proteoglycans (ofCSPGs) in the urine of bladder cancer patients as an
indication of disease presence. We show that ofCSPGs in bladder cancer urine can be immobilized on cationic
nitrocellulose membranes and subsequently probed for ofCS content by rVAR2 protein in a custom-made dot-blot
assay. Patients with high-grade bladder tumors displayed a marked increase in urinary ofCSPGs as compared to
healthy individuals. Urine ofCSPGs decreased significantly after complete tumor resection compared to matched urine
collected preoperatively from patients with bladder cancer. Moreover, ofCSPGs in urine correlated with tumor size of
bladder cancer patients. These findings demonstrate that rVAR2 can be utilized in a simple biochemical assay to detect
cancer-specific ofCS-modifications in the urine of bladder cancer patients, which may be further developed as a
noninvasive approach to detect and monitor the disease.
Introduction
Bladder cancer is the fifth most common cancer in the
world and one of the most expensive cancers to treat on a
per-patient basis due to the need for constant surveillance
and multiple therapeutic interventions1,2. Urinary bio-
markers in bladder cancer have been researched for
decades with the aim of noninvasive detection of disease
and to monitor high-risk patients with nonmuscle inva-
sive bladder cancer (NMIBC)3–5. While several urine
biomarkers have been identified over the years, novel
biomarkers with high sensitivity and specificity are in
demand5.
Chondroitin Sulfate (CS) is a glycosaminoglycan
(GAG) linked to specific proteoglycans (CSPGs) present
in the cell membranes, or secreted into the extracellular
matrix and bodily fluids6. CS chains are comprised of
linear polysaccharides made up of repeated N-acetyl-D-
galactosamine (GalNAc) and Glucuronic Acid (GlcA)
disaccharide units and can vary greatly in length. While
the basic structure is simple, an immense structural
heterogeneity is achieved through modifications of the
carbohydrate backbone, such as sulfation of component
hydroxyl groups. The nontemplate driven synthesis
ofCS that vary in size and sulfation patterns makes CS
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amongst the most heterogeneous molecules in the
human body7.
Bladder cancer, like most other solid tumors, expresses
a distinct form of chondroitin sulfate (CS), normally
restricted to the placenta8. In the placenta, this CS mod-
ification plays a key role in the lifecycle of Plasmodium
falciparum malaria parasites. During malaria infections,
the malaria parasite expresses specific host-anchor pro-
teins on the surface of infected erythrocytes, which
enables them to adhere to the vascular bed and avoid
destruction in the spleen9. Depending on the anchor-
protein expressed, infected erythrocytes can adhere to
different organs in the human body including brain, lung,
heart, and placenta10. The placenta-specific malaria
tropism is mediated by the parasite-encoded host-anchor-
protein VAR2CSA, which facilitates specific adherence of
infected erythrocytes to placental CS chains with no
adhesion to any other tissues in the human body, despite
CS being present on many cells of the human host11. The
strict specificity for CS in the placenta indicates the pre-
sence of a unique CS variant structurally distinct from
other CS types, and that the malarial VAR2CSA has been
evolutionarily optimized for selectivity against this sub-
type ofCS only12. Interestingly, ofCS is also expressed in
most types of solid tumors8. The re-expression of a fetal
antigen is consistent with the idea that cancers revert to a
less differentiated (or fetal) state during disease progres-
sion to facilitate proliferation, migration, and other
oncogenic processes. Because of the similarities between
placenta and tumors, recombinant malarial VAR2CSA
(rVAR2) can be conveniently utilized to detect ofCS in
cancers and facilitate delivery of toxic payloads to tumors
in vivo, including cisplatin resistant bladder cancer8,13.
Several studies have reported changes in GAG con-
centration and composition in bodily fluids in a variety of
pathologies, including cancer14–20. In fact, changes in the
urine GAG composition have been previously suggested
as a biomarker for detection of cancers, including ovarian
and clear cell renal carcinoma14,19,21. In vitro detection of
GAGs in bladder cancer urine dates back to the early
1980s where Hennessey and Cutter described a potential
relationship between increased GAG urine content and
disease progression22. However, utility of urinary GAG
analyses in bladder cancer has been limited partly due to
the lack of appropriate methodology for detection of
specific cancer-associated GAG subtypes. Several meth-
ods have been developed for the detection of GAGs in
urine including precipitation with cationic dyes, electro-
phoresis, and capture and detection of specific structures
in ELISA type assays15,16,18,19,21. Despite these efforts,
cancer-specific GAG analyses of urine samples remain a
technological challenge.
Bladder cancer has been reported to display changes in
expression of GAGs and CSPGs in different stages of the
disease. For example, high overall intratumor GAG con-
tent has been shown to correlate with bladder tumor
grade and stage23,24. Some GAG subtypes such as ofCS
are selectively expressed in malignancies, including blad-
der cancer8,13. Indeed, ofCS has been described to be
highly expressed at various stages of bladder cancer where
high ofCS levels correlate with resistance to chemother-
apy and predicts poor survival of patients13. Also, CSPGs
such as SDC1 and CSPG4 are highly expressed in bladder
cancer and these CSPGs can indeed be modified with
ofCS in a redundant manner, increasing the overall
amount of ofCS in the tumors13. For those reasons, we
decided to test whether rVAR2 could be used to detect
cancer-derived ofCS in the urine of bladder cancer
patients as an indication of disease. We thus developed a
method to probe ofCS in urine from bladder cancer
patients using a simple biochemical assay with rVAR2 as
the detection reagent.
Results
Oncofetal chondroitin sulfate can be detected in urine
from bladder cancer patients
For optimization of the assay, nitrocellulose membranes
were treated with two different concentrations of cationic
detergents, cetylpyridinium chloride (CPC) or benzyalk-
onium chloride (BAC). The treated membranes were then
inserted into a dot-blot apparatus and a titration of
chondroitin sulfate type A (CSA) in PBS was filtered
through. Immobilization of CSA was observed with an
Alcian Blue stain that stains most types of charged poly-
saccharides. We observed that both captured CS in a
concentration-dependent manner as stained by Alcian
Blue, but CPC facilitated marginally better binding to CS
over BAC in this setting (Fig. 1a). While there is some CS
present in the urine in free form, a large majority of the
CS is attached to CSPG. To test whether rVAR2 could
detect immobilized ofCSPGs from a liquid solution, we
used purified bovine decorin, which contains CSA-
modifications detectable by rVAR28. In this analysis, we
immobilized different concentrations of CSA-containing
decorin in PBS onto BAC membranes and probed with
rVAR2. Indeed, rVAR2 was able to detect CSA-modified
decorin in a concentration-dependent manner (Fig. 1b).
We then tested the system on urine from bladder cancer
patients. Interestingly, when probing immobilized urine
samples from high grade (HG) and low grade (LG) blad-
der cancer patients, as well as healthy individuals (H1-4)
with rVAR2, strong reactivity was observed in the HG
group (Fig. 1c). Also, rVAR2 binding to immobilized CSA
was slightly better over background (BG) on BAC treated
membranes as compared to membranes treated with CPC
at different concentrations (Fig. 1c). Based on these
results, treatment of the membranes with 0.5% BAC and
blocking in 3% gelatin was used for all subsequent
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experiments. These data demonstrate that malarial
rVAR2 protein can be used to probe for immobilized
ofCS-modified proteoglycans in a BAC-primed dot-blot
assay.
A simple dot-blot assay for urinary oncofetal chondroitin
sulfate analysis
We next tested the dot-blot assay on urine samples
originating from a mixed cohort of bladder and prostate
cancer patients and healthy controls. There was clear
differential staining between rVAR2 and Alcian Blue in
this cohort (Fig. 2a). Moreover, when focussing specifi-
cally on bladder cancer (Vancouver Cohort, Table 1) and
using Alcian Blue as normalization, higher ofCS levels
were observed in patients versus healthy individuals (Fig. 2b).
Notably, we could also detect increased ofCSPG levels in a
cohort of metastatic kidney cancer patients (Fig. 2c). We
next tested whether urinary creatinine would perform
better for normalization of the rVAR2-HRP signal as
compared with Alcian Blue. The rationale for this was that
urinary creatinine excretion rates are relatively constant
amongst different individuals and within an individual
over time, thereby providing a control for urine con-
centration independent of overall GAG concentration.
Moreover, creatinine has been frequently used for nor-
malizations in urine biomarker applications and its
method of detection well established25–27. With urinary
creatinine normalization, there was a better separation of
cancer patients and healthy individuals as compared to
Alcian Blue (Fig. 2d). We therefore concluded that nor-
malization to urinary creatinine would be more accurate
for clinical proof-of-concept analysis and we hence per-
formed the remainder of the study as per outlined in the
experimental workflow (Fig. 2e).
Urinary oncofetal chondroitin sulfate reports on disease
status pre and postsurgery
Using our rVAR2-based dot-blot assay (Fig. 2e), we next
examined the feasibility of using ofCSPGs as a urinary
biomarker for the detection of bladder cancer in three
separate validation cohorts obtained from the Leeds
Institute of Cancer and Pathology, the University of the
Basque Country, Spain and from the University Hospital
Tübingen. We observed a significant increase in the
presence of urinary ofCS in patients with bladder cancer
compared to healthy individuals and individuals who
previously presented bladder cancer, but were disease-free
at the time of urine collection in both the UK (Fig. 3a) and
Spain (Fig. 3b) cohorts. We additionally observed a trend
towards significance in the German cohort (Fig. 3c).
Furthermore, we saw disappearance of urinary ofCS in 5/5
patients after trans-urothelial resection of bladder tumors
(TURBT) or cystectomy, and persistent ofCS content in
one patient with residual disease after TURBT (Fig. 3d).
Urinary oncofetal chondroitin sulfate detection depends
on tumor size and grade
To further substantiate the data, we attempted to
determine the correlation between tumor grade and the
expression of urinary ofCS. In our first validation cohort
(UK), we observed a significant increase in ofCS expres-
sion in patients with high-grade tumors only (Fig. 4a). The
same pattern was observed in the second validation cohort
(Spain) (Fig. 4b). Tumor size was available in the Spanish
cohort, and we were able to demonstrate a significant
correlation between tumor size and ofCS expression
regardless of grade (Fig. 4c). Interestingly, there appeared
to a bimodal distribution of ofCS expression across a
number of different disease stages that we analyzed—
particularly in the larger, more aggressive tumors. Finally,
we did an aggregate score to reflect the contribution of
Fig. 1 Soluble and protein bound ofCS detected by dot blot.
a Different concentrations of CSA were dissolved in PBS and
immobilized on a CPC or BAC derivatized membrane using a dot-blot
apparatus following which, the membrane was stained with 10%
(w/v) Alcian Blue. b Different concentrations of decorin were dissolved
in PBS and tested similarly with rVAR2-HRP and Alcian Blue as
described above. c Nitrocellulose membranes were derivatized using
different concentration of either CPC vs. BAC and urine samples from
cancer patients and healthy controls were applied to immobilize all
the GAGs present in urine. The membranes were stained with rVAR2-
HRP and visualized using enhanced chemiluminesence reagent.
Following this, the membrane was stained with 10% (w/v) alcian blue.
(CPC cetylpyridinium chloride, BAC benzalkonium chloride, BG
background, HG high grade, LG low grade, H healthy individuals,
S1 replicate1, S2 replicate 2).
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size in the context of grade and repeated our analysis. The
highest urinary ofCS levels were found in patients with
large high-grade tumors (Fig. 4d).
Discussion
A dot-blot assay developed by Karlsson et al., in which
GAGs in urine were filtered through a membrane
Fig. 2 Bladder cancer detection based on ofCS expression in urine. a A full array of urine samples from the “training cohort” was immobilized on
a BAC derivatized membrane and staining with rVAR2-HRP (ofCS) and Alcian Blue was carried out as described previously. Intensity of Alcian Blue
staining was measured using the ImageStudio software. b Comparison ofCS readouts from patients with bladder cancer versus healthy individuals
with ofCS expression readouts normalized to Alcian Blue. c Comparison ofCS readouts from patients with metastatic kidney cancer versus healthy
individuals as in b. d Urinary creatinine in the samples was measured using a colorimetric assay kit. The difference in total glycan normalized ofCS
expression between healthy and bladder cancer patients and difference in urinary creatinine normalized ofCS expression between healthy and
bladder cancer patients was calculated on R. e Schematic representation of modified assay workflow. Boxes represent the 25th to 75th percentile
with means at the 50th percentile and whiskers extend to the highest and lowest values within 1.5× of the upper and lower quartile distance with
outliers shown as dots. Mann–Whitney test: *p < 0.05; **p < 0.01; ***p < 0.001.
Table 1 Summary of clinical bladder cancer cohorts.
Characteristics Discovery cohort Validation cohort Validation cohort Validation cohort
Vancouver, Canada
(N= 136)
Tübingen, Germany
(N= 198)
Leeds, UK (N= 100) Madrid, Spain (N= 136)
Clinical context Screening and
surveillance
Surveillance Surveillance Screening and
surveillance
Bladder cancer status, n (%)
Present (1) 66 (48.5%) 88 (44.4%) 80 (80%) 106 (77.9%)
Absent (0) 70 (51.5%) 110 (55.6%) 20 (20%) 30 (22.1%)
Clinical T stage, n (%)
Tis 5 (7.6%) 5 (5.7%) 4 (5%) 0 (0)
Ta 17 (25.8%) 54 (61.4%) 56 (70%) 39 (36.8%)
I 13 (19.7%) 10 (11.4%) 9 (11.3%) 45 (42.4%)
II 21 (31.8%) 13 (14.7%) 8 (10%) 19 (17.9%)
III 6 (9.1%) 6 (6.8%) 2 (2.5%) 3 (2.8%)
IV 5 (7.6%) 0 (0%) 1 (1.3%) 0 (0)
Grade, n (%) (a)
I LG 10 (15.1%) 23 (26.1%) 11 (13.8%) LG 65 (61.3%)
II HG 56 (84.9%) 30 (34.1%) 34 (42.5%) HG 41 (38.7%)
III 30 (34.1%) 35 (46%)
Summary of the cancer cohorts used in this study. The terms “screening” and “surveillance” signify the classification of disease-free individuals. In the surveillance
cohorts, all patients classified as negative were disease-free at the urine collection but had a prior history of bladder cancer. In the screening and surveillance cohorts,
patients classified as negative either had a prior history of bladder but were disease-free at the time of sample collection or had no prior history of bladder cancer but
had other urologic pathologies.
aSpecimens classified as Tis did not have a grade assigned.
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derivatized with a cationic detergent to allow for capture
of polyanionic polysaccharides28. This assay allows for
probing of specific GAG structures in the immobilized
samples using lectins or structure specific antibodies29. As
a further consideration, specific detection of GAG struc-
tures in immobilized samples has previously been shown
to be dependent on the detergent used, despite sufficient
immobilization29. We therefore reasoned that using a
Fig. 3 Validation of ofCS expression in different cohorts. a Expression analysis of ofCS between cancer-free individuals (normal) and bladder
cancer patients in the UK cohort (n= 100) was carried out using the methods described previously and all data were analyzed using R. b Expression
analysis of ofCS between cancer-free individuals and bladder cancer patients in the Spain cohort (n= 136). c Expression analysis of ofCS between
cancer-free individuals and bladder cancer patients at the time of urine collection in the Tubingen Cohort (n= 198). d Urine samples of patients (n=
6) before and after treatment (tumor resection or cystectomy) were measured for ofCS expression and compared. Boxes represent the 25th to 75th
percentile with means at the 50th percentile and whiskers extend to the highest and lowest values within 1.5× of the upper and lower quartile
distance with outliers shown as dots. Mann–Whitney test: ***p < 0.001.
Fig. 4 Urine ofCS expression is affected by both grade and size of tumor. a Urinary creatinine normalized expression of of CS expression based
on tumor grade in patients from the UK cohort (n= 80) was analyzed on R. b Urinary creatinine normalized expression analysis of ofCS expression
based on tumor grade in patients from the Spain cohort (n= 106). c Urinary creatinine normalized expression analysis of ofCS expression relative to
tumor size in patients from the Spain cohort. (Score: 1—less than 2 cm; 2–2 cm to 4 cm; 3—more than 4 cm). d Comparison of urinary ofCS
expression in Spain cohort patients relative to both size and grade. Boxes represent the 25th to 75th percentile with means at the 50th percentile and
whiskers extend to the highest and lowest values within 1.5× of the upper and lower quartile distance with outliers shown as dots. (Scoring metric:
low grade= 1; high grade= 2. Overall score= grade score+ size score). (Legend: H—Cancer-free; LG—Low-grade; HG—High-grade).
Mann–Whitney test: *p < 0.05; **p < 0.01; ***p < 0.001.
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modified version of this assay, we should be able to probe
urine samples for the presence of ofCS using rVAR2 given
that rVAR2 specifically binds to ofCS8. Densitometry
readings of the dot blot further allowed us to analyze the
amount of ofCS present in the urine, thereby providing us
with a quantitative measurement for the detection of
urinary ofCS.
The results presented here suggest that urinary ofCS
detection might be informative in the context of disease
surveillance after TURBT or cystectomy and could
potentially be a low-cost alternative to the current sur-
veillance methods. While the UK and Spain cohorts
exhibit a significant difference in ofCS expression between
cancer-free and cancer-positive patients, this was not
immediately apparent in the German cohort. We suspect
that this minor deviation from significance could be due
to the presence of outliers possibly attributed to differ-
ences in sample collection protocols, which were not
standardized across the different cohorts. Furthermore,
this cohort is biased in respect to tumor stage as a large
number of tumors are of stage Ta. Since noninvasive, Ta
tumors generally have low ofCS expression, this would
likely be a confounding factor in particular cohort. The
result from the German cohort becomes significant if a
formal correction for outliers is performed.
Outliers as observed in the boxplot analyses could be
attributed to other confounding variables that we were
not able to account for in our cohorts, such as presence of
additional urologic malignancies in individual patients, as
well as differences in sample-to-sample liquid biopsy
collection, and processing procedures. Collectively, our
data signify that ofCS may be a candidate urinary bio-
marker for detection of bladder cancer.
Our data also demonstrate that ofCS is present in the
urine of patients with bladder cancer in a grade- and
tumor size-dependent manner. The finding that ofCS is
also present in urine from kidney cancer patients suggests
the possibility that changes in urine ofCSPG levels may be
informative in additional cancer types. While highly
intriguing, the clinical utility of ofCSPGs in urine remains
to be explored. With disease-specific GAG binders such
as rVAR2, we may be able to increase the resolution
of GAG analyses in urine and develop informative non-
invasive diagnostic, prognostic, or surveillance tools for
future clinical use.
Materials and methods
Patient cohorts
The use of all patient samples was approved by the
University of British Columbia’s Research Ethics Com-
mittee as the GU BioBank (approval number—H09-
01628). Written consent was obtained from the patients.
For the Vancouver discovery cohort, patients undergoing
evaluation for initial presentation with symptoms of
bladder cancer and those under surveillance for prior
bladder cancer had their urine collected and banked. All
collected samples were aliquoted and stored at −80 °C
until needed for analysis. Our validation cohorts were
obtained from the Leeds Institute of Cancer Studies,
Pathology Universidad Pontificia de Salamanca and
Eberhard–Karls University. The previously published
cohort of metastatic renal cancer was provided by Dr.
Umberto Basso (Istituto Oncologico Veneto IOV—
IRCCS)20. An overview of the bladder cancer patient urine
cohorts used in the validation is summarized in Table 1.
Dot blot
For dot--blot analysis, 1 mL aliquots of urine were
thawed immediately before use and centrifuged at
3000 rpm to remove any cellular debris from the samples.
The supernatant was then used for further downstream
analysis. To begin the dot-blot assay, derivatization of
0.45 um PVDF membrane (Millipore Sigma, IPVH00010)
was carried out by submersing the membrane into a 0.5%
(w/v) benzalkonium chloride (Sigma, B-1383) in 30%
2-propanol solution. This was followed by four rounds of
incubation and rinses with 150mM NaCl solution to coat
the membrane with an overall positive charge. The
charged membrane was then placed inside a dot-blot
apparatus and 20 uL per sample of urine samples were
applied to the membrane. Subsequently, the membrane
was blocked with 3% (w/v) gelatin for an hour followed by
incubation with 4 µg/mL rVAR2 in 1.5% (w/v) gelatin for
1 h or overnight at 4 °C. The membranes were then
washed and proved with a secondary HRP antibody tar-
geting the V5 tag on rVAR2. Stained membranes were
developed with SuperSignal™ West Femto Maximum
Sensitivity Substrate (Thermo, 34095).
Alcian blue staining
To carry out alcian blue staining, alcian blue was pre-
pared by diluting a 20× alcian blue stock in 0.4M GuHCl,
0.018 M Sulfuric Acid, 0.25% Triton-X. The membrane
was then stained with the 1× alcian blue solution for 2 h
at room temperature, following which, a 30 min wash
step in 0.4M GuHCl, 0.018M Sulfuric Acid, 0.25%
Triton-X was carried out. A final rinse with 150 mM
sodium chloride was then carried out before analysis of
the staining.
Urinary creatinine measurements
All ofCS expression readouts (rVAR2-HRP) were nor-
malized to urinary creatinine levels measured in the cor-
responding samples. Urinary creatinine was measured using
the Creatinine (urinary) Colorimetric Assay Kit (Cayman
Chemicals, 500701) according to manufacturer’s protocol.
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Statistical analyses
Graphing and statistical analyses were carried using the
R software. The ofCS expression was statistically analyzed
and significance, where indicated, was calculated using the
Mann–Whitney test. Significance was determined as a
p-value < 0.05. All analysis was carried out in a blinded
manner wherein the clinical status of the patients was not
revealed until after the analysis. No statistical method was
used to predetermine patient sample size.
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